Investor Information

SUBLOCADETM (buprenorphine extended-release) Injection for Subcutaneous Use (CIII)

SUBLOCADE was approved by the FDA in the U.S. on November 30, 2017

View press release here

View full U.S. Prescribing Information, including BOXED Warning here


Along with Indivior’s robust pipeline of lifecycle products and innovative product development, our investors are what help make our vision such a demonstrable success. View important investor information here.

See more